专利检索 ap:("The Trustees of Columbia University in the City of New York") AND inv:"RABADAN, Raul" 第 1 页

1.

发明公开
FUSION PROTEINS AND METHODS THEREOF 审中-公开
标题翻译：融合蛋白及其方法

公开(公告)号：EP2968551A1

公开(公告)日：2016-01-20

申请号：EP14769771.8

申请日：2014-03-13

申请人： The Trustees of Columbia University in the City of New York

发明人： IAVARONE, Antonio , LASORELLA, Anna , RABADAN, Raul

IPC分类号： A61K39/395

CPC分类号： C12N9/12 , A61K31/404 , A61K31/4439 , A61K31/47 , A61K31/496 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/53 , A61K38/179 , C07K14/435 , C07K14/47 , C07K14/4738 , C07K14/71 , C07K16/40 , C07K2317/76 , C07K2319/00 , C12N9/16 , C12Q1/6886 , C12Y207/10001 , C12Y301/03003 , G01N33/573 , G01N33/57484 , G01N2333/71 , A61K2300/00

摘要： The invention discloses oncogenic fusion proteins. The invention provides methods for treating gene-fusion based cancers.

2.

发明授权
TECHNIQUES FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 有权

公开(公告)号：EP2917374B1

公开(公告)日：2019-03-27

申请号：EP13853653.7

申请日：2013-11-06

申请人： The Trustees of Columbia University in the City of New York

发明人： FERRANDO, Adolfo , RABADAN, Raul , PALOMERO, Teresa

IPC分类号： G01N33/574 , C12Q1/68 , A61K31/52 , A61K31/7076

3.

发明公开
TECHNIQUES FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 审中-公开
标题翻译：方法急性淋巴细胞白血病的治疗

公开(公告)号：EP2917374A1

公开(公告)日：2015-09-16

申请号：EP13853653.7

申请日：2013-11-06

申请人： The Trustees of Columbia University in the City of New York

发明人： FERRANDO, Adolfo , RABADAN, Raul , PALOMERO, Teresa

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 , A61K31/52 , A61K31/7076 , C12Q2600/156 , G01N33/57426 , G01N2333/916

摘要： The invention is based on the discovery of certain new somatic single nucleotide substitution mutations of NT5C2 gene variants found in some Acute Lymphoblastic Leukemia (ALL) relapse subjects. Techniques include obtaining a biological sample taken from a subject having ALL, and detecting the presence or absence in the biological sample of a biomarker selected from the group consisting of an NT5C2 gene mutation, an mRNA transcribed from the NT5C2 gene mutation, or a protein encoded by the NT5C2 gene mutation. The method also includes determining that the subject has increased resistance to treatment with 6-mercaptopurine or 6-thioguanine, if the biomarker is detected. In some embodiments, the method still further includes treating the subject with a nucleoside analog other than 6-mercaptopurine or 6-thioguanine if the biomarker is detected.